Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Visani

Showing results (191-200 of 211) with videos related to

Pageof 22
Sort By:
Bone Marrow Transplantation|September 14, 1999
Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cellsG Visani, R Lemoli, P Tosi, et al.
Blood|November 5, 1997
Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission: a European Group for Blood and Marrow Transplantation study. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)A Ferrant, M Labopin, F Frassoni, et al.
Bone Marrow Transplantation|July 31, 2001
Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patientsG Visani, R M Lemoli, A Isidori, et al.
British Journal of Haematology|June 3, 1999
Fludarabine-containing regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukaemia patientsG Visani, R M Lemoli, P Tosi, et al.
British Journal of Haematology|September 6, 2000
No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)J Y Cahn, M Labopin, J Sierra, et al.
Leukemia|May 23, 2001
Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemiaG Visani, D Milligan, F Leoni, et al.
Blood|May 1, 1996
Interleukin-9 stimulates the proliferation of human myeloid leukemic cellsR M Lemoli, A Fortuna, A Tafuri, et al.
European Journal of Haematology|December 17, 1998
Acute promyelocytic leukaemia: epidemiology and risk factors. A report of the GIMEMA Italian archive of adult acute leukaemia. GIMEMA Cooperative GroupA Pulsoni, A Stazi, R Cotichini, et al.
Leukemia|March 1, 1996
Autologous bone marrow transplantation in late first complete remission improves outcome in acute myelogenous leukemiaM C Miggiano, F Gherlinzoni, G Rosti, et al.
Leukemia|April 29, 1998
All-trans retinoic acid (ATRA) in patients with chronic myeloid leukemia in the chronic phaseD Russo, M Regazzi, S Sacchi, et al.
Pageof 22

Showing results (191-200 of 211) with videos related to

Sort By:
Pageof 22
Bone Marrow Transplantation|September 14, 1999
Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cellsG Visani, R Lemoli, P Tosi, et al.
Blood|November 5, 1997
Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission: a European Group for Blood and Marrow Transplantation study. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)A Ferrant, M Labopin, F Frassoni, et al.
Bone Marrow Transplantation|July 31, 2001
Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patientsG Visani, R M Lemoli, A Isidori, et al.
British Journal of Haematology|June 3, 1999
Fludarabine-containing regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukaemia patientsG Visani, R M Lemoli, P Tosi, et al.
British Journal of Haematology|September 6, 2000
No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)J Y Cahn, M Labopin, J Sierra, et al.
Leukemia|May 23, 2001
Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemiaG Visani, D Milligan, F Leoni, et al.
Blood|May 1, 1996
Interleukin-9 stimulates the proliferation of human myeloid leukemic cellsR M Lemoli, A Fortuna, A Tafuri, et al.
European Journal of Haematology|December 17, 1998
Acute promyelocytic leukaemia: epidemiology and risk factors. A report of the GIMEMA Italian archive of adult acute leukaemia. GIMEMA Cooperative GroupA Pulsoni, A Stazi, R Cotichini, et al.
Leukemia|March 1, 1996
Autologous bone marrow transplantation in late first complete remission improves outcome in acute myelogenous leukemiaM C Miggiano, F Gherlinzoni, G Rosti, et al.
Leukemia|April 29, 1998
All-trans retinoic acid (ATRA) in patients with chronic myeloid leukemia in the chronic phaseD Russo, M Regazzi, S Sacchi, et al.
Pageof 22